{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:37:09Z","timestamp":1788053829321,"version":"build-2784847793"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Grants in Aid for Scientific Research","doi-asserted-by":"crossref","award":["24K19695"],"award-info":[{"award-number":["24K19695"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11912-024-01615-5","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T05:05:25Z","timestamp":1730783125000},"page":"1563-1574","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7045-8151","authenticated-orcid":false,"given":"Yuji","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2919-6337","authenticated-orcid":false,"given":"Tsukuru","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7331-7621","authenticated-orcid":false,"given":"Akiko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2585-9271","authenticated-orcid":false,"given":"Akimasa","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-9082","authenticated-orcid":false,"given":"Akie","family":"Takebayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8183-9702","authenticated-orcid":false,"given":"Tetsuro","family":"Hanada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3945-6817","authenticated-orcid":false,"given":"Shunichiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0250-0856","authenticated-orcid":false,"given":"Takashi","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"key":"1615_CR1","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1634\/theoncologist.2014-0016","volume":"19","author":"KF Trivers","year":"2014","unstructured":"Trivers KF, Fink AK, Partridge AH, Oktay K, Ginsburg ES, Li C, et al. Estimates of young breast cancer survivors at risk for infertility in the U.S. Oncologist. 2014;19:814\u201322. https:\/\/doi.org\/10.1634\/theoncologist.2014-0016.","journal-title":"Oncologist"},{"key":"1615_CR2","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1191\/0961203306lu2291oa","volume":"15","author":"HI Brunner","year":"2006","unstructured":"Brunner HI, Bishnoi A, Barron AC, Houk LJ, Ware A, Farhey Y, et al. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus. 2006;15:198\u2013206. https:\/\/doi.org\/10.1191\/0961203306lu2291oa.","journal-title":"Lupus"},{"key":"1615_CR3","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3899\/jrheum.100130","volume":"38","author":"Z Touma","year":"2011","unstructured":"Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Mycophenolate mofetil for induction treatment of lupus nephritis: A systematic review and metaanalysis. J Rheumatol. 2011;38:69\u201378. https:\/\/doi.org\/10.3899\/jrheum.100130.","journal-title":"J Rheumatol"},{"key":"1615_CR4","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2174\/1389201018666170808122531","volume":"18","author":"RB Danis","year":"2017","unstructured":"Danis RB, Pereira N, Elias RT. Random start ovarian stimulation for oocyte or embryo cryopreservation in women desiring fertility preservation prior to gonadotoxic cancer therapy. Curr Pharm Biotechnol. 2017;18:609\u201313. https:\/\/doi.org\/10.2174\/1389201018666170808122531.","journal-title":"Curr Pharm Biotechnol"},{"key":"1615_CR5","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1471-2407-13-240","volume":"13","author":"KD Yu","year":"2013","unstructured":"Yu KD, Huang S, Zhang JX, Liu GY, Shao ZM. Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: A systematic review and meta-analysis. BMC Cancer. 2013;13:240. https:\/\/doi.org\/10.1186\/1471-2407-13-240.","journal-title":"BMC Cancer"},{"key":"1615_CR6","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1001\/jamaoncol.2015.3856","volume":"2","author":"M Chavez-MacGregor","year":"2016","unstructured":"Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol. 2016;2:322\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3856.","journal-title":"JAMA Oncol"},{"key":"1615_CR7","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/humrep\/deac035","volume":"37","author":"L Arecco","year":"2022","unstructured":"Arecco L, Blondeaux E, Bruzzone M, Ceppi M, Latocca MM, Marrocco C, et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: A systematic review and meta-analysis. Hum Reprod. 2022;37:954\u201368. https:\/\/doi.org\/10.1093\/humrep\/deac035.","journal-title":"Hum Reprod"},{"key":"1615_CR8","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1093\/humrep\/dex027","volume":"32","author":"RJ Rodgers","year":"2017","unstructured":"Rodgers RJ, Reid GD, Koch J, Deans R, Ledger WL, Friedlander M, et al. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: A systematic review. Hum Reprod. 2017;32:1033\u201345. https:\/\/doi.org\/10.1093\/humrep\/dex027.","journal-title":"Hum Reprod"},{"key":"1615_CR9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1080\/09513590.2016.1177013","volume":"32","author":"N Pereira","year":"2016","unstructured":"Pereira N, Hancock K, Cordeiro CN, Lekovich JP, Schattman GL, Rosenwaks Z. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes\u2020. Gynecol Endocrinol. 2016;32:823\u20136. https:\/\/doi.org\/10.1080\/09513590.2016.1177013.","journal-title":"Gynecol Endocrinol"},{"key":"1615_CR10","doi-asserted-by":"publisher","unstructured":"Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: A guideline. Fertil Steril. 2013;99:37\u201343. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.09.028","DOI":"10.1016\/j.fertnstert.2012.09.028"},{"key":"1615_CR11","doi-asserted-by":"publisher","first-page":"e0168277","DOI":"10.1371\/journal.pone.0168277","volume":"12","author":"ITA Peters","year":"2017","unstructured":"Peters ITA, van Zwet EW, Smit VTHBM, Liefers GJ, Kuppen PJK, Hilders CGJM, et al. Prevalence and risk factors of ovarian metastases in breast cancer patients < 41 years of age in the Netherlands: A nationwide retrospective cohort study. PLoS One. 2017;12:e0168277. https:\/\/doi.org\/10.1371\/journal.pone.0168277.","journal-title":"PLoS One"},{"key":"1615_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ygyno.2005.06.065","volume":"100","author":"A Finch","year":"2006","unstructured":"Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58\u201364. https:\/\/doi.org\/10.1016\/j.ygyno.2005.06.065.","journal-title":"Gynecol Oncol"},{"key":"1615_CR13","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s10815-013-0065-3","volume":"30","author":"V Luyckx","year":"2013","unstructured":"Luyckx V, Durant JF, Camboni A, Gilliaux S, Amorim CA, Van Langendonckt A, et al. Is transplantation of cryopreserved ovarian tissue from patients with advanced-stage breast cancer safe? A pilot study. J Assist Reprod Genet. 2013;30:1289\u201399. https:\/\/doi.org\/10.1007\/s10815-013-0065-3.","journal-title":"J Assist Reprod Genet"},{"key":"1615_CR14","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.fertnstert.2021.03.008","volume":"115","author":"MM Dolmans","year":"2021","unstructured":"Dolmans MM, von Wolff M, Poirot C, Diaz-Garcia C, Cacciottola L, Boissel N, et al. Transplantation of cryopreserved ovarian tissue in a series of 285 women: A review of five leading European centers. Fertil Steril. 2021;115:1102\u201315. https:\/\/doi.org\/10.1016\/j.fertnstert.2021.03.008.","journal-title":"Fertil Steril"},{"key":"1615_CR15","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.fertnstert.2014.06.003","volume":"102","author":"WS Vitek","year":"2014","unstructured":"Vitek WS, Shayne M, Hoeger K, Han Y, Messing S, Fung C. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: A systematic review and meta-analysis. Fertil Steril. 2014;102:808-815.e1. https:\/\/doi.org\/10.1016\/j.fertnstert.2014.06.003.","journal-title":"Fertil Steril"},{"key":"1615_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jamaoncol.2015.3251","volume":"2","author":"RR Munhoz","year":"2016","unstructured":"Munhoz RR, Pereira AAL, Sasse AD, Hoff PM, Traina TA, Hudis CA, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: A systematic review and meta-analysis. JAMA Oncol. 2016;2:65\u201373. https:\/\/doi.org\/10.1001\/jamaoncol.2015.3251.","journal-title":"JAMA Oncol"},{"key":"1615_CR17","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1200\/JCO.2018.78.0858","volume":"36","author":"M Lambertini","year":"2018","unstructured":"Lambertini M, Moore HCF, Leonard RCF, Loibl S, Munster P, Bruzzone M, et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: A systematic review and meta-analysis of individual patient-level data. J Clin Oncol. 2018;36:1981\u201390. https:\/\/doi.org\/10.1200\/JCO.2018.78.0858.","journal-title":"J Clin Oncol"},{"key":"1615_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1159\/000528028","volume":"18","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Zhang C, Lei X, Ren T, Chen H, Zhao Q. Gonadotropin-releasing hormone agonists during gonadal chemotherapy for the effect on pregnancy outcome and ovarian function in premenopausal patients with breast cancer: A systematic review and meta-analysis. Breast Care (Basel). 2023;18:270\u20138. https:\/\/doi.org\/10.1159\/000528028.","journal-title":"Breast Care (Basel)"},{"key":"1615_CR19","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1200\/JCO.2018.78.1914","volume":"36","author":"K Oktay","year":"2018","unstructured":"Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2018;36:1994\u20132001. https:\/\/doi.org\/10.1200\/JCO.2018.78.1914.","journal-title":"J Clin Oncol"},{"key":"1615_CR20","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/j.annonc.2020.09.006","volume":"31","author":"M Lambertini","year":"2020","unstructured":"Lambertini M, Peccatori FA, Demeestere I, Amant F, Wyns C, Stukenborg JB, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines\u2020. Ann Oncol. 2020;31:1664\u201378. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.006.","journal-title":"Ann Oncol"},{"key":"1615_CR21","doi-asserted-by":"publisher","first-page":"hoaa052","DOI":"10.1093\/hropen\/hoaa052","volume":"2020","author":"RA Anderson","year":"2020","unstructured":"ESHRE Guideline Group on Female Fertility Preservation, Anderson RA, Amant F, Braat D, D\u2019Angelo A, de Sousa C, Lopes SM, et al. [ESHRE guideline]. ESHRE guideline: Female fertility preservation. Hum Reprod Open. 2020;2020:hoaa052. https:\/\/doi.org\/10.1093\/hropen\/hoaa052.","journal-title":"Hum Reprod Open"},{"key":"1615_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10549-022-06650-z","volume":"195","author":"Y Wang","year":"2022","unstructured":"Wang Y, Tesch ME, Lim C, Xu YH, Lee S, Perdizet K, et al. Risk of recurrence and pregnancy outcomes in young women with breast cancer who do and do not undergo fertility preservation. Breast Cancer Res Treat. 2022;195:201\u20138. https:\/\/doi.org\/10.1007\/s10549-022-06650-z.","journal-title":"Breast Cancer Res Treat"},{"key":"1615_CR23","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s10815-022-02394-3","volume":"39","author":"M Salama","year":"2022","unstructured":"Salama M, Lambertini M, Christianson MS, Jayasinghe Y, Anazodo A, De Vos M, et al. Installing oncofertility programs for breast cancer in limited versus optimum resource settings: Empirical data from 39 surveyed centers in Repro-Can-OPEN Study Part I & II. J Assist Reprod Genet. 2022;39:505\u201316. https:\/\/doi.org\/10.1007\/s10815-022-02394-3.","journal-title":"J Assist Reprod Genet"},{"key":"1615_CR24","doi-asserted-by":"publisher","first-page":"690320","DOI":"10.3389\/fonc.2021.690320","volume":"11","author":"E Blondeaux","year":"2021","unstructured":"Blondeaux E, Massarotti C, Fontana V, Poggio F, Arecco L, Fregatti P, et al. The PREgnancy and FERtility (PREFER) study investigating the need for ovarian function and\/or fertility preservation strategies in premenopausal women with early breast cancer. Front Oncol. 2021;11:690320. https:\/\/doi.org\/10.3389\/fonc.2021.690320.","journal-title":"Front Oncol"},{"key":"1615_CR25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.breast.2022.05.006","volume":"64","author":"M Duraes","year":"2022","unstructured":"Duraes M, Rathat G, Bringer-Deutsch S, Ranisavljevic N, Brouillet S, Defez-Fougeron C, et al. Fertility preservation in patients of childbearing age treated for breast cancer: A nationwide cohort study. Breast. 2022;64:121\u20136. https:\/\/doi.org\/10.1016\/j.breast.2022.05.006.","journal-title":"Breast"},{"key":"1615_CR26","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1007\/s10815-023-02968-9","volume":"40","author":"M Swain","year":"2023","unstructured":"Swain M, Miller M, Cannella C, Daviskiba S. Disparities in fertility preservation among patients diagnosed with female breast cancer. J Assist Reprod Genet. 2023;40:2843\u20139. https:\/\/doi.org\/10.1007\/s10815-023-02968-9.","journal-title":"J Assist Reprod Genet"},{"key":"1615_CR27","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1007\/s10815-023-02850-8","volume":"40","author":"MT Sauerbrun-Cutler","year":"2023","unstructured":"Sauerbrun-Cutler MT, Pandya S, Recabo O, Raker C, Clark MA, Robison K. Survey of young women with breast cancer to identify rates of fertility preservation (FP) discussion and barriers to FP care. J Assist Reprod Genet. 2023;40:2003\u201311. https:\/\/doi.org\/10.1007\/s10815-023-02850-8.","journal-title":"J Assist Reprod Genet"},{"key":"1615_CR28","doi-asserted-by":"publisher","first-page":"4418","DOI":"10.1038\/s41598-024-54961-6","volume":"14","author":"S Mannion","year":"2024","unstructured":"Mannion S, Higgins A, Larson N, Stewart EA, Khan Z, Shenoy C, et al. Prevalence and impact of fertility concerns in young women with breast cancer. Sci Rep. 2024;14:4418. https:\/\/doi.org\/10.1038\/s41598-024-54961-6.","journal-title":"Sci Rep"},{"key":"1615_CR29","doi-asserted-by":"publisher","first-page":"9645","DOI":"10.1038\/s41598-023-36377-w","volume":"13","author":"JKY Ko","year":"2023","unstructured":"Ko JKY, Cheung CSY, Cheng HHY, Yung SSF, Ng TY, Tin WWY, et al. Knowledge, attitudes and intention on fertility preservation among breast cancer patients. Sci Rep. 2023;13:9645. https:\/\/doi.org\/10.1038\/s41598-023-36377-w.","journal-title":"Sci Rep"},{"key":"1615_CR30","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.fertnstert.2009.03.045","volume":"94","author":"AH Partridge","year":"2010","unstructured":"Partridge AH, Ruddy KJ, Gelber S, Schapira L, Abusief M, Meyer M, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril. 2010;94:638\u201344. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.03.045.","journal-title":"Fertil Steril"},{"key":"1615_CR31","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1200\/JCO.19.00126","volume":"38","author":"HA Kim","year":"2020","unstructured":"Kim HA, Lee JW, Nam SJ, Park BW, Im SA, Lee ES, et al. Adding ovarian suppression to tamoxifen for premenopausal breast cancer: A randomized phase III trial. J Clin Oncol. 2020;38:434\u201343. https:\/\/doi.org\/10.1200\/JCO.19.00126.","journal-title":"J Clin Oncol"},{"key":"1615_CR32","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1186\/s12885-017-3593-x","volume":"17","author":"A Wenners","year":"2017","unstructured":"Wenners A, Grambach J, Koss J, Maass N, Jonat W, Schmutzler A, et al. Reduced ovarian reserve in young early breast cancer patients: Preliminary data from a prospective cohort trial. BMC Cancer. 2017;17:632. https:\/\/doi.org\/10.1186\/s12885-017-3593-x.","journal-title":"BMC Cancer"},{"key":"1615_CR33","doi-asserted-by":"publisher","first-page":"9217","DOI":"10.3390\/curroncol30100666","volume":"30","author":"\u00c7 \u00dcnal","year":"2023","unstructured":"\u00dcnal \u00c7, Ordu \u00c7, \u00d6zmen T, \u0130lgun AS, \u00c7elebi F, Baysal B, et al. Evaluation of anti-Mullerian hormone levels, antral follicle counts, and mean ovarian volumes in chemotherapy-induced amenorrhea among breast cancer patients: A prospective clinical study. Curr Oncol. 2023;30:9217\u201329. https:\/\/doi.org\/10.3390\/curroncol30100666.","journal-title":"Curr Oncol"},{"key":"1615_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.52054\/FVVO.15.4.102","volume":"15","author":"J Servayge","year":"2023","unstructured":"Servayge J, Verduyn AC, Page A, Lagaert L, Tjalma WAA. Clinical guidelines for managing menopausal symptoms in women with (a history of) breast cancer. Facts Views Vis Obgyn. 2023;15:297\u2013308. https:\/\/doi.org\/10.52054\/FVVO.15.4.102.","journal-title":"Facts Views Vis Obgyn"},{"key":"1615_CR35","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMoa0909638","volume":"362","author":"SM Swain","year":"2010","unstructured":"Swain SM, Jeong JH, Geyer CE, Costantino JP, Pajon ER, Fehrenbacher L, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med. 2010;362:2053\u201365. https:\/\/doi.org\/10.1056\/NEJMoa0909638.","journal-title":"N Engl J Med"},{"key":"1615_CR36","doi-asserted-by":"publisher","unstructured":"Corrigendum. J Natl Cancer Inst. 2019;111:1237. https:\/\/doi.org\/10.1093\/jnci\/djy197.","DOI":"10.1093\/jnci\/djy197"},{"key":"1615_CR37","doi-asserted-by":"publisher","first-page":"859974","DOI":"10.3389\/fonc.2022.859974","volume":"12","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li Y, Liang J, Zhang N, Yang Q. Chemotherapy-induced amenorrhea and its prognostic significance in premenopausal women with breast cancer: An updated meta-analysis. Front Oncol. 2022;12:859974. https:\/\/doi.org\/10.3389\/fonc.2022.859974.","journal-title":"Front Oncol"},{"key":"1615_CR38","doi-asserted-by":"publisher","unstructured":"American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and Practice Committee. Female age-related fertility decline. Committee Opinion No. 589. Fertil Steril. 2014;101:633\u20134. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.12.032","DOI":"10.1016\/j.fertnstert.2013.12.032"},{"key":"1615_CR39","doi-asserted-by":"publisher","first-page":"702446","DOI":"10.3389\/fendo.2021.702446","volume":"12","author":"K Papageorgiou","year":"2021","unstructured":"Papageorgiou K, Mastora E, Zikopoulos A, Grigoriou ME, Georgiou I, Michaelidis TM. Interplay between mTOR and hippo signaling in the ovary: Clinical choice guidance between different gonadotropin preparations for better IVF. Front Endocrinol (Lausanne). 2021;12:702446. https:\/\/doi.org\/10.3389\/fendo.2021.702446.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1615_CR40","doi-asserted-by":"publisher","first-page":"e12552","DOI":"10.1002\/rmb2.12552","volume":"23","author":"Y Katagiri","year":"2024","unstructured":"Katagiri Y, Jwa SC, Kuwahara A, Iwasa T, On M, Kato K, et al. Assisted reproductive technology in Japan: A summary report for 2021 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology. Reprod Med Biol. 2024;23:e12552. https:\/\/doi.org\/10.1002\/rmb2.12552.","journal-title":"Reprod Med Biol"},{"key":"1615_CR41","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2021.03.017","volume":"151","author":"HJ Kim","year":"2021","unstructured":"Kim HJ, Noh WC, Nam SJ, Park BW, Lee ES, Im SA, et al. Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report. Eur J Cancer. 2021;151:190\u2013200. https:\/\/doi.org\/10.1016\/j.ejca.2021.03.017.","journal-title":"Eur J Cancer"},{"key":"1615_CR42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s10549-020-05933-7","volume":"185","author":"SB Goldfarb","year":"2021","unstructured":"Goldfarb SB, Turan V, Bedoschi G, Taylan E, Abdo N, Cigler T, et al. Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer. Breast Cancer Res Treat. 2021;185:165\u201373. https:\/\/doi.org\/10.1007\/s10549-020-05933-7.","journal-title":"Breast Cancer Res Treat"},{"key":"1615_CR43","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.fertnstert.2016.10.020","volume":"107","author":"LM Shandley","year":"2017","unstructured":"Shandley LM, Spencer JB, Fothergill A, Mertens AC, Manatunga A, Paplomata E, et al. Impact of tamoxifen therapy on fertility in breast cancer survivors. Fertil Steril. 2017;107:243-252.e5. https:\/\/doi.org\/10.1016\/j.fertnstert.2016.10.020.","journal-title":"Fertil Steril"},{"key":"1615_CR44","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00404-017-4594-3","volume":"297","author":"AN Sch\u00fcring","year":"2018","unstructured":"Sch\u00fcring AN, Fehm T, Behringer K, Goeckenjan M, Wimberger P, Henes M, et al. Practical recommendations for fertility preservation in women by the FertiPROTEKT network. Part I: Indications for fertility preservation. Arch Gynecol Obstet. 2018;297:241\u201355. https:\/\/doi.org\/10.1007\/s00404-017-4594-3.","journal-title":"Arch Gynecol Obstet"},{"key":"1615_CR45","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.1002\/cncr.33596","volume":"127","author":"T Sella","year":"2021","unstructured":"Sella T, Poorvu PD, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, et al. Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. Cancer. 2021;127:2888\u201394. https:\/\/doi.org\/10.1002\/cncr.33596.","journal-title":"Cancer"},{"key":"1615_CR46","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1056\/NEJMoa2212856","volume":"388","author":"AH Partridge","year":"2023","unstructured":"Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, et al. Interrupting endocrine therapy to attempt pregnancy after breast cancer. N Engl J Med. 2023;388:1645\u201356. https:\/\/doi.org\/10.1056\/NEJMoa2212856.","journal-title":"N Engl J Med"},{"key":"1615_CR47","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1200\/JCO.2010.29.7689","volume":"29","author":"PA Ganz","year":"2011","unstructured":"Ganz PA, Land SR, Geyer CE, Cecchini RS, Costantino JP, Pajon ER, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol. 2011;29:1110\u20136. https:\/\/doi.org\/10.1200\/JCO.2010.29.7689.","journal-title":"J Clin Oncol"},{"key":"1615_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10549-014-2914-x","volume":"145","author":"J Zhao","year":"2014","unstructured":"Zhao J, Liu J, Chen K, Li S, Wang Y, Yang Y, et al. What lies behind chemotherapy-induced amenorrhea for breast cancer patients: A meta-analysis. Breast Cancer Res Treat. 2014;145:113\u201328. https:\/\/doi.org\/10.1007\/s10549-014-2914-x.","journal-title":"Breast Cancer Res Treat"},{"key":"1615_CR49","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1200\/JCO.1996.14.5.1718","volume":"14","author":"J Bines","year":"1996","unstructured":"Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14:1718\u201329. https:\/\/doi.org\/10.1200\/JCO.1996.14.5.1718.","journal-title":"J Clin Oncol"},{"key":"1615_CR50","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s10549-015-3426-z","volume":"151","author":"KJ Ruddy","year":"2015","unstructured":"Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, et al. Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015;151:589\u201396. https:\/\/doi.org\/10.1007\/s10549-015-3426-z.","journal-title":"Breast Cancer Res Treat"},{"key":"1615_CR51","doi-asserted-by":"publisher","first-page":"575","DOI":"10.3389\/fonc.2019.00575","volume":"9","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Olympios N, Lequesne J, Calbrix C, Fontanilles M, Loeb A, et al. Impact of taxanes, endocrine therapy, and deleterious germline BRCA mutations on anti-M\u00fcllerian hormone levels in early breast cancer patients treated with anthracycline- and cyclophosphamide-based chemotherapy. Front Oncol. 2019;9:575. https:\/\/doi.org\/10.3389\/fonc.2019.00575.","journal-title":"Front Oncol"},{"key":"1615_CR52","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1200\/JCO.2017.72.3494","volume":"35","author":"B Ejlertsen","year":"2017","unstructured":"Ejlertsen B, Tuxen MK, Jakobsen EH, Jensen MB, Knoop AS, H\u00f8jris I, et al. Adjuvant cyclophosphamide and docetaxel with or without epirubicin for early TOP2A-normal breast cancer: DBCG 07-READ, an open-label, phase III, randomized trial. J Clin Oncol. 2017;35:2639\u201346. https:\/\/doi.org\/10.1200\/JCO.2017.72.3494.","journal-title":"J Clin Oncol"},{"key":"1615_CR53","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1093\/humrep\/dew224","volume":"31","author":"C Silva","year":"2016","unstructured":"Silva C, Caramelo O, Almeida-Santos T, Ribeiro Rama AC. Factors associated with ovarian function recovery after chemotherapy for breast cancer: A systematic review and meta-analysis. Hum Reprod. 2016;31:2737\u201349. https:\/\/doi.org\/10.1093\/humrep\/dew224.","journal-title":"Hum Reprod"},{"key":"1615_CR54","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jnci\/djy094","volume":"111","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Campbell C, Bines J, Korde LA, Izquierdo M, Fumagalli D, et al. Adjuvant anti-HER2 therapy, treatment-related amenorrhea, and survival in premenopausal HER2-positive early breast cancer patients. J Natl Cancer Inst. 2019;111:86\u201394. https:\/\/doi.org\/10.1093\/jnci\/djy094.","journal-title":"J Natl Cancer Inst"},{"key":"1615_CR55","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41523-021-00307-8","volume":"7","author":"PD Poorvu","year":"2021","unstructured":"Poorvu PD, Hu J, Zheng Y, Gelber SI, Ruddy KJ, Tamimi RM, et al. Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. npj Breast Cancer. 2021;7:99. https:\/\/doi.org\/10.1038\/s41523-021-00307-8.","journal-title":"npj Breast Cancer"},{"key":"1615_CR56","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10549-020-05692-5","volume":"182","author":"T Iwamoto","year":"2020","unstructured":"Iwamoto T, Hara F, Uemura Y, Mukai H, Watanabe T, Ohashi Y. NSAS-BC02 substudy of chemotherapy-induced amenorrhea (CIA) in premenopausal patients who received either taxane alone or doxorubicin(A) cyclophosphamide(C) followed by taxane as postoperative chemotherapy. Breast Cancer Res Treat. 2020;182:325\u201332. https:\/\/doi.org\/10.1007\/s10549-020-05692-5.","journal-title":"Breast Cancer Res Treat"},{"key":"1615_CR57","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1093\/jnci\/djab065","volume":"113","author":"KD Yu","year":"2021","unstructured":"Yu KD, Ge JY, Liu XY, Mo M, He M, Shao ZM, et al. Cyclophosphamide-free adjuvant chemotherapy for ovarian protection in young women with breast cancer: A randomized phase 3 trial. J Natl Cancer Inst. 2021;113:1352\u20139. https:\/\/doi.org\/10.1093\/jnci\/djab065.","journal-title":"J Natl Cancer Inst"},{"key":"1615_CR58","doi-asserted-by":"publisher","first-page":"pkz081","DOI":"10.1093\/jncics\/pkz081","volume":"3","author":"KC Gast","year":"2019","unstructured":"Gast KC, Cathcart-Rake EJ, Norman AD, Eshraghi L, Obidegwu N, Nichols HB, et al. Regimen-specific rates of chemotherapy-related amenorrhea in breast cancer survivors. JNCI Cancer Spec. 2019;3:pkz081. https:\/\/doi.org\/10.1093\/jncics\/pkz081.","journal-title":"JNCI Cancer Spec"},{"key":"1615_CR59","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ygyno.2011.01.003","volume":"121","author":"LE Weinberg","year":"2011","unstructured":"Weinberg LE, Lurain JR, Singh DK, Schink JC. Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. Gynecol Oncol. 2011;121:285\u20139. https:\/\/doi.org\/10.1016\/j.ygyno.2011.01.003.","journal-title":"Gynecol Oncol"},{"key":"1615_CR60","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ygyno.2008.05.033","volume":"111","author":"H Kang","year":"2008","unstructured":"Kang H, Kim TJ, Kim WY, Choi CH, Lee JW, Kim BG, et al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol. 2008;111:106\u201310. https:\/\/doi.org\/10.1016\/j.ygyno.2008.05.033.","journal-title":"Gynecol Oncol"},{"key":"1615_CR61","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41523-021-00264-2","volume":"7","author":"PA Ganz","year":"2021","unstructured":"Ganz PA, Cecchini RS, Fehrenbacher L, Geyer CE, Rastogi P, Crown JP, et al. NRG Oncology\/NSABP B-47 menstrual history study: Impact of adjuvant chemotherapy with and without trastuzumab. npj Breast Cancer. 2021;7:55. https:\/\/doi.org\/10.1038\/s41523-021-00264-2.","journal-title":"npj Breast Cancer"},{"key":"1615_CR62","doi-asserted-by":"publisher","first-page":"33","DOI":"10.6004\/jnccn.2022.7065","volume":"21","author":"M Lambertini","year":"2023","unstructured":"Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, et al. Impact of anti-HER2 therapy alone and with weekly paclitaxel on the ovarian reserve of young women with HER2-positive breast cancer. J Natl Compr Canc Netw. 2023;21:33-41.e16. https:\/\/doi.org\/10.6004\/jnccn.2022.7065.","journal-title":"J Natl Compr Canc Netw"},{"key":"1615_CR63","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/biomedicines8120577","volume":"8","author":"M Levi","year":"2020","unstructured":"Levi M, Goshen-Lago T, Yerushalmi R, Granot T, Stemmer SM, Shalgi R, et al. Anti-HER2\/neu antibody reduces chemotherapy-induced ovarian toxicity-from bench to bedside. Biomedicines. 2020;8:577. https:\/\/doi.org\/10.3390\/biomedicines8120577.","journal-title":"Biomedicines"},{"key":"1615_CR64","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.annonc.2022.03.076","volume":"33","author":"J Furlanetto","year":"2022","unstructured":"Furlanetto J, Marm\u00e9 F, Thode C, Nekljudova V, Liu Y, Martin Jimenez M, et al. 60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B. Ann Oncol. 2022;33:S149\u201350. https:\/\/doi.org\/10.1016\/j.annonc.2022.03.076.","journal-title":"Ann Oncol"},{"key":"1615_CR65","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/jnci\/djab066","volume":"113","author":"M Lambertini","year":"2021","unstructured":"Lambertini M, Partridge AH. Cyclophosphamide-free adjuvant chemotherapy for the potential prevention of premature ovarian insufficiency and infertility in young women with breast cancer. J Natl Cancer Inst. 2021;113:1274\u20136. https:\/\/doi.org\/10.1093\/jnci\/djab066.","journal-title":"J Natl Cancer Inst"},{"key":"1615_CR66","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1002\/cncr.30421","volume":"123","author":"T Watanabe","year":"2017","unstructured":"Watanabe T, Kuranami M, Inoue K, Masuda N, Aogi K, Ohno S, et al. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer. 2017;123:759\u201368. https:\/\/doi.org\/10.1002\/cncr.30421.","journal-title":"Cancer"},{"key":"1615_CR67","doi-asserted-by":"publisher","first-page":"R55","DOI":"10.1186\/bcr3156","volume":"14","author":"THM Keegan","year":"2012","unstructured":"Keegan THM, DeRouen MC, Press DJ, Kurian AW, Clarke CA. Occurrence of breast cancer subtypes in adolescent and young adult women. Breast Cancer Res. 2012;14:R55. https:\/\/doi.org\/10.1186\/bcr3156.","journal-title":"Breast Cancer Res"},{"key":"1615_CR68","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/jnci\/djab111","volume":"113","author":"W Cui","year":"2021","unstructured":"Cui W, Francis PA, Loi S, Hickey M, Stern C, Na L, et al. Assessment of ovarian function in phase III (neo)adjuvant breast cancer clinical trials: A systematic evaluation. J Natl Cancer Inst. 2021;113:1770\u20138. https:\/\/doi.org\/10.1093\/jnci\/djab111.","journal-title":"J Natl Cancer Inst"},{"key":"1615_CR69","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.breast.2022.05.002","volume":"64","author":"W Cui","year":"2022","unstructured":"Cui W, Phillips KA, Francis PA, Anderson RA, Partridge AH, Loi S, et al. Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials. Breast. 2022;64:56\u201362. https:\/\/doi.org\/10.1016\/j.breast.2022.05.002.","journal-title":"Breast"},{"key":"1615_CR70","doi-asserted-by":"publisher","first-page":"e415","DOI":"10.1016\/S1470-2045(23)00390-X","volume":"24","author":"W Cui","year":"2023","unstructured":"Cui W, Rocconi RP, Thota R, Anderson RA, Bruinooge SS, Comstock IA, et al. Measuring ovarian toxicity in clinical trials: An American Society of Clinical Oncology research statement. Lancet Oncol. 2023;24:e415\u201323. https:\/\/doi.org\/10.1016\/S1470-2045(23)00390-X.","journal-title":"Lancet Oncol"},{"key":"1615_CR71","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.annonc.2020.03.284","volume":"31","author":"S Paluch-Shimon","year":"2020","unstructured":"Paluch-Shimon S, Cardoso F, Partridge AH, Abulkhair O, Azim HA, Bianchi-Micheli G, et al. ESO-ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). Ann Oncol. 2020;31:674\u201396. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.284.","journal-title":"Ann Oncol"},{"key":"1615_CR72","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.ejca.2020.11.032","volume":"144","author":"RA Anderson","year":"2021","unstructured":"Anderson RA, Clatot F, Demeestere I, Lambertini M, Morgan A, Nelson SM, et al. Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments. Eur J Cancer. 2021;144:310\u20136. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.032.","journal-title":"Eur J Cancer"},{"key":"1615_CR73","doi-asserted-by":"publisher","first-page":"485","DOI":"10.21147\/j.issn.1000-9604.2020.04.06","volume":"32","author":"Q Li","year":"2020","unstructured":"Li Q, Wang J, Mu Y, Zhang T, Han Y, Wang J, et al. Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer. Chin J Cancer Res. 2020;32:485\u201396. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2020.04.06.","journal-title":"Chin J Cancer Res"},{"key":"1615_CR74","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1001\/jamaoncol.2020.2965","volume":"6","author":"KD Yu","year":"2020","unstructured":"Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: A phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1390\u20136. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2965.","journal-title":"JAMA Oncol"},{"key":"1615_CR75","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10549-020-05648-9","volume":"182","author":"F Du","year":"2020","unstructured":"Du F, Wang W, Wang Y, Li M, Zhu A, Wang J, et al. Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Res Treat. 2020;182:67\u201377. https:\/\/doi.org\/10.1007\/s10549-020-05648-9.","journal-title":"Breast Cancer Res Treat"},{"key":"1615_CR76","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejca.2018.10.015","volume":"106","author":"A Schneeweiss","year":"2019","unstructured":"Schneeweiss A, M\u00f6bus V, Tesch H, Hanusch C, Denkert C, L\u00fcbbe K, et al. Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto-GBG 84): A randomised phase III trial. Eur J Cancer. 2019;106:181\u201392. https:\/\/doi.org\/10.1016\/j.ejca.2018.10.015.","journal-title":"Eur J Cancer"},{"key":"1615_CR77","doi-asserted-by":"publisher","first-page":"e230122","DOI":"10.1001\/jamanetworkopen.2023.0122","volume":"6","author":"P Yuan","year":"2023","unstructured":"Yuan P, Kang Y, Ma F, Fan Y, Wang J, Wang X, et al. Effect of epirubicin plus paclitaxel vs epirubicin and cyclophosphamide followed by paclitaxel on disease-free survival among patients with operable ERBB2-negative and lymph node-positive breast cancer: A randomized clinical trial. JAMA Netw Open. 2023;6:e230122. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.0122.","journal-title":"JAMA Netw Open"},{"key":"1615_CR78","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273\u201383. https:\/\/doi.org\/10.1056\/NEJMoa0910383.","journal-title":"N Engl J Med"},{"key":"1615_CR79","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018;379:111\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1804710.","journal-title":"N Engl J Med"},{"key":"1615_CR80","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentj\u00e9 VO, et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): A multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:1630\u201340. https:\/\/doi.org\/10.1016\/S1470-2045(18)30570-9.","journal-title":"Lancet Oncol"},{"key":"1615_CR81","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24:2278\u201384. https:\/\/doi.org\/10.1093\/annonc\/mdt182.","journal-title":"Ann Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01615-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-024-01615-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01615-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T05:20:54Z","timestamp":1734153654000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-024-01615-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":81,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1615"],"URL":"https:\/\/doi.org\/10.1007\/s11912-024-01615-5","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"11 October 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research Involving Human Participants and\/or Animals"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}]}}